Fluviral®

BIOLOGICAL6 trials

Sponsors

GlaxoSmithKline, University Health Network, Toronto

Conditions

InfluenzaInfluenza VaccinesInfluenza, HumanTransplantation

Phase 3

A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine

CompletedNCT00505453

GlaxoSmithKlineInfluenza

Start: 2007-07-31End: 2007-08-31Target: 110Updated: 2016-11-04

Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years

CompletedNCT00718120

GlaxoSmithKlineInfluenza Vaccines

Start: 2008-07-18End: 2008-08-09Updated: 2019-06-26

Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years

CompletedNCT00929331

GlaxoSmithKlineInfluenza, Human

Start: 2009-07-11End: 2009-08-01Updated: 2020-11-09

Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years

CompletedNCT01153685

GlaxoSmithKlineInfluenza

Start: 2010-07-09End: 2010-07-31Updated: 2018-06-08

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults

CompletedNCT01626820

GlaxoSmithKlineInfluenza

Start: 2012-07-19End: 2012-08-10Updated: 2018-09-07

Phase 4

Adjuvanted Influenza Vaccine in Stem Cell Transplant

CompletedNCT02560909

University Health Network, TorontoInfluenza Vaccines, Transplantation

Start: 2015-10-31End: 2016-08-31Updated: 2017-04-10

Related Papers

A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine.

2014-03-105 citations